NanoViricides is trading at $1.63 (up 5.4%), extending yesterday’s jump after Noble Capital Markets initiated coverage on the stock with an Outperform rating and a $6.00 price target.
- The rally is fueled by positive updates regarding NV-387, the company’s broad-spectrum antiviral candidate, which is currently moving toward Phase II clinical trials.
- The $6.00 price target implies significant upside potential, contributing to sustained buying pressure following yesterday's initial move.
- While broader market indices are modestly higher, the price action is primarily driven by these company-specific clinical and analyst catalysts.